Incyte Corporation is a global biopharmaceutical company that discovers, develops, and commercializes novel medicines to address serious unmet medical needs. The company operates primarily through two therapeutic franchises: Hematology/Oncology and Inflammation/Autoimmunity. Its cornerstone product is Jakafi (ruxolitinib), a targeted therapy for myelofibrosis, polycythemia vera, and graft-versus-host disease that generates the majority of its revenue. Incyte's commercial portfolio also includes Opzelura, a topical JAK inhibitor for atopic dermatitis and vitiligo, as well as targeted oncology drugs like Pemazyre, Monjuvi, and Zynyz. Beyond its marketed products, the company maintains a robust clinical pipeline of small molecules and biologics. Originally founded as a genomics information company in 1991, Incyte successfully pivoted to internal drug discovery in the early 2000s and now operates research and commercial facilities across North America, Europe, and Asia.
